Wealthquest Corp Takes Position in Repligen Corporation (NASDAQ:RGEN)

Wealthquest Corp acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 2,077 shares of the biotechnology company’s stock, valued at approximately $264,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Utah Retirement Systems grew its position in Repligen by 1.1% in the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 100 shares in the last quarter. State of Michigan Retirement System boosted its stake in shares of Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after purchasing an additional 100 shares during the period. Louisiana State Employees Retirement System grew its holdings in Repligen by 0.7% during the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after purchasing an additional 100 shares in the last quarter. Peapack Gladstone Financial Corp increased its stake in Repligen by 5.2% during the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company’s stock worth $301,000 after buying an additional 103 shares during the period. Finally, Signaturefd LLC lifted its holdings in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after buying an additional 128 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. Barclays began coverage on shares of Repligen in a research report on Tuesday, June 24th. They set an “overweight” rating and a $150.00 price target for the company. Canaccord Genuity Group cut their price target on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a report on Wednesday, April 16th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Sunday, June 29th. Finally, Royal Bank Of Canada boosted their target price on shares of Repligen from $193.00 to $204.00 and gave the stock an “outperform” rating in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $169.45.

Repligen Trading Down 4.7%

Repligen stock opened at $117.07 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The firm’s 50-day moving average is $123.46 and its 200-day moving average is $136.78. The company has a market cap of $6.58 billion, a P/E ratio of -468.26, a PEG ratio of 2.27 and a beta of 1.11.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The business’s revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 EPS. On average, equities analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.